April 16, 2014

No Evidence That Ezetimibe Benefits Health

Pills Spilling out of Pill Bottle No Evidence That Ezetimibe Benefits Health

by Dr. John Briffa
The Cholesterol Truth

Excerpts:

Ezetimibe is a cholesterol-reducing drug. Unlike statins (which reduce cholesterol production in the liver), ezetimibe blocks the absorption of cholesterol from the gut. It’s generally very effective at reducing cholesterol levels. On this basis, the Food and Drugs Administration (FDA) licensed ezetimibe for use in the treatment of raised cholesterol in 2002. It’s been quite a bestseller too, racking up sales in the order of $4 billion dollars annually.

However, there is a dark underbelly to the rip-roaring success of ezetimibe. While it’s effective at reducing cholesterol, to date no study has found that it helps reduce truly important things like the risk of heart attack and death. In fact, there is some evidence that it might do more harm than good. For example, 2008 saw the publication of the so-called ENHANCE study which found that adding ezetimibe to simvastatin (a statin) led to an increase in the thickness of artery walls in the neck compared to simvastatin alone (though the difference was not statistically significant). So underwhelming (or concerning) were these results to the manufacturer, that they were kept under wraps for 2 years before the US government forced their publication.

Read the full article and comment here: http://www.thecholesteroltruth.com/no-evidence-that-ezetimibe-benefits-health/

 

Fat and Cholesterol are Good for You!
What REALLY Causes Heart Disease
by Uffe Ravnskov, MD, PhD

fat and cholesterol are good for you No Evidence That Ezetimibe Benefits Health

Free Shipping Available!


0 commentsback to post

Other articlesgo to homepage

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

Congressman Bill Posey’s strong resolve and demands for transparency were evident as he discussed the Center for Disease Control (CDC)’s handling of vaccine safety studies which affect “our most precious resource in our nation – our children.” The 30-minute interview, conducted by vaccine industry watchdog, PhD biochemist Brian Hooker, delves into what Posey called “the incestuous relationship between the public health community and the vaccine makers and public officials.”

The Florida legislator, known as “Mr. Accountabililty,” did not mince words when criticizing current and past CDC officials including indicted fraudster Dr. Poul Thorsen; CDC director turned Merck Vaccine President Dr. Julie Gerberding; and the agency’s current spokesperson regarding autism and vaccines, Dr. Coleen Boyle.

Congressman Posey said, “The CDC can’t be trusted regarding investigating vaccine safety. Huge conflict of interest. I think the CDC should be investigated.”

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

In an interview with Dr. Bernard Dalbergue, a former pharmaceutical industry physician with Gardasil manufacturer Merck, he predicts that Gardasil will become the greatest medical scandal of all time. Dr. Dalbergue believes that at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer and that all the very many adverse effects which destroy lives and even kill young girls, serves no other purpose than to generate profit for the manufacturers.

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

An important new book by a recognized medical research expert describes Big Pharma as akin to the Mafia. In an interview conducted by our colleagues at ANH-Europe, Dr. Peter C. Gøtzsche exposes the flaws of the drug approval system, our reliance on dangerous drugs, and the deadly co-dependence between regulators and industry. Dr. Gøtzsche is co-founder of the highly respected Cochrane Collaboration and Cochrane Reviews, a leading journal of evidence-based medicine. The interview is particularly timely now that the FDA has decided to remove restrictions on the dangerous drug Avandia.

Dr. Gøtzsche’s new book, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare, points out that the pharmaceutical industry is allowed to test their own drugs, and thus effectively be their own judge. He calls this a threat to safe medicine and asks for open access to all research data, including raw data, because otherwise, data can be easily suppressed and conclusions manipulated by industry.

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical marijuana, or cannabis, is legal in 20 US states, where it is used for a variety of medical conditions such as mood disorders, pain disorders, multiple sclerosis, and even cancer. Parents of children with epilepsy met at a news conference to share their dismay that Governor Mark Dayton refuses to legalize medical marijuana. About 85 percent to 95 percent of Americans are in favor of medical cannabis, and nearly 60 percent are in favor of legalizing marijuana. Cannabis shows outstanding promise as a medicinal plant, largely due to its cannabidiol (CBD) content. Cannabinoids interact with your body by way of naturally occurring cannabinoid receptors embedded in cell membranes throughout your body.

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published recently in the Journal of the American Medical Association.

A team of researchers at the University of Pittsburgh Medical Center examined the boards of the 50 largest drug companies by global sales (excluding three companies that were not publicly traded). The researchers found that 40 percent — 19 companies — had at least one board member who also held a leadership role at an academic medical center. Sixteen of the 17 companies based in the United States had at least one. Several had more than one. All told, the research team found that 41 of the companies’ 2012 board members held leadership positions at academic medical centers. Six of the 41 were pharmaceutical company executives who served on hospital boards of directors or held other leadership posts.

The authors wrote that when academic medical leaders serve on pharmaceutical company boards, it can lead to conflicts not only for individuals, but for the critically important health care institutions they guide.

read more


Get the news right in your inbox!